• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Vera Therapeutics (VERA) Undervalued After TRUTAKNA Launch Momentum And FDA Filing?

    Simply Wall St·11/09/2026 13:25:55
    Listen to the news

    Vera Therapeutics (VERA) is back in focus after third quarter results showed a net loss of US$93.71 million, as the company leans into the TRUTAKNA launch and files for full FDA approval.

    Against this backdrop, Vera Therapeutics’ share price has retreated over the year, with a year-to-date share price return of negative 38.74%, even as the 1-year total shareholder return of 7.33% and 3-year total shareholder return of 133.42% point to earlier momentum driven by expectations around TRUTAKNA and its regulatory path.

    Capitalize on Vera Therapeutics’ TRUTAKNA momentum by scanning a curated set of immunology and biotech plays already filtered for quality through 19 high quality undiscovered gems.

    Bulls point to TRUTAKNA traction and a steep discount to some valuation estimates. Bears focus on heavy losses and execution risk. Which case does Vera Therapeutics’ current pricing reflect?

    Most Popular Narrative: 62% Undervalued

    Vera Therapeutics last closed at $29.79, while the analyst consensus Narrative on Simply Wall St points to a fair value of $77.50 using a 7.57% discount rate. That gap frames a story built around TRUTAKNA scale up and long term earnings power.

    The full two year ORIGIN 3 data set for TRUTAKNA, including a 5.0 ml per year treatment delta in eGFR slope and a 76% risk reduction on a composite kidney endpoint, supports wider physician confidence in BAFF/APRIL modulation. This can expand TRUTAKNA adoption and lift revenue and operating leverage as fixed commercial costs are spread over more treated patients.

    See why 1 investors see Vera Therapeutics as 62% undervalued.

    Result: Fair Value of $77.50 (UNDERVALUED)

    Still, the bullish Vera Therapeutics story frays quickly if TRUTAKNA uptake trails analyst projections or investors refuse to pay a nearly 79x 2029 P/E.

    Find out about the key risks to this Vera Therapeutics narrative.

    Next Steps

    Curious whether the bullish tone on Vera Therapeutics matches your own read of the facts today, not last quarter or next year? Put the numbers in context for yourself by checking the 2 key rewards.

    Looking for more investment ideas beyond Vera Therapeutics?

    If Vera Therapeutics has sharpened your thinking, do not stop here. Broaden your watchlist with focused screeners that help you act with intent, not impulse.